China Health Group Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Ho Chung

İcra Kurulu Başkanı

HK$1.2m

Toplam tazminat

CEO maaş yüzdesi	98.5%
CEO görev süresi	7yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	6.8yrs
Yönetim Kurulu ortalama görev süresi	9.3yrs

Son yönetim güncellemeleri

Here's Why China Health Group Limited's (HKG:673) CEO Compensation Is The Least Of Shareholders' Concerns

Sep 05

Shareholders Will Probably Not Have Any Issues With China Health Group Limited's (HKG:673) CEO Compensation

Sep 11

Recent updates

Here's Why China Health Group Limited's (HKG:673) CEO Compensation Is The Least Of Shareholders' Concerns

Sep 05

Shareholders Will Probably Not Have Any Issues With China Health Group Limited's (HKG:673) CEO Compensation

Sep 11

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

Dec 01

We Discuss Why China Health Group Limited's (HKG:673) CEO May Deserve A Higher Pay Packet

Sep 23

We Think Some Shareholders May Hesitate To Increase China Health Group Limited's (HKG:673) CEO Compensation

Sep 02

Did China Health Group Limited (HKG:673) Insiders Sell Shares?

Feb 16

CEO Tazminat Analizi

Ho Chung'un ücretlendirmesi China Health Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-HK$43m
Jun 30 2024	n/a	n/a	-HK$41m
Mar 31 2024	HK$1m	HK$1m	-HK$40m
Dec 31 2023	n/a	n/a	-HK$35m
Sep 30 2023	n/a	n/a	-HK$29m
Jun 30 2023	n/a	n/a	-HK$36m
Mar 31 2023	HK$1m	HK$1m	-HK$42m
Dec 31 2022	n/a	n/a	-HK$38m
Sep 30 2022	n/a	n/a	-HK$35m
Jun 30 2022	n/a	n/a	-HK$23m
Mar 31 2022	HK$2m	HK$1m	-HK$12m
Dec 31 2021	n/a	n/a	-HK$11m
Sep 30 2021	n/a	n/a	-HK$9m
Jun 30 2021	n/a	n/a	-HK$8m
Mar 31 2021	HK$2m	HK$1m	-HK$8m
Dec 31 2020	n/a	n/a	-HK$23m
Sep 30 2020	n/a	n/a	-HK$38m
Jun 30 2020	n/a	n/a	-HK$37m
Mar 31 2020	HK$2m	HK$1m	-HK$37m
Dec 31 2019	n/a	n/a	-HK$29m
Sep 30 2019	n/a	n/a	-HK$22m
Jun 30 2019	n/a	n/a	-HK$22m
Mar 31 2019	HK$2m	HK$2m	-HK$23m
Dec 31 2018	n/a	n/a	-HK$24m
Sep 30 2018	n/a	n/a	-HK$25m
Jun 30 2018	n/a	n/a	-HK$32m
Mar 31 2018	HK$2m	HK$2m	-HK$39m

Tazminat ve Piyasa: Ho 'nin toplam tazminatı ($USD 156.91K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 230.88K ).

Tazminat ve Kazançlar: Ho 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ho Chung (61 yo)

7yrs

Görev süresi

HK$1,218,000

Tazminat

Mr. Ho Chung has been an Executive Director at China Health Group Limited since December 28, 2012 and has been its Chief Executive Officer since December 11, 2017. Mr. Chung has an experience in investment...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Fan Zhang	Executive Chairman	8yrs	HK$1.22m	27.93% HK$ 50.8m
Ho Chung	CEO & Executive Director	7yrs	HK$1.22m	Veri yok
Yong Xing	Executive Director	less than a year	HK$300.00k	0.028% HK$ 51.7k
Jiuru Ding	Chief Financial Officer	6.8yrs	Veri yok	Veri yok
Amy Yu	Chief Operating Officer and Vice President	no data	Veri yok	Veri yok
Siu Hung Tsui	Company Secretary	15.8yrs	Veri yok	Veri yok
Peiyuan Qiu	Senior Consultant	5.3yrs	HK$130.00k	Veri yok

6.8yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: 673 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Fan Zhang	Executive Chairman	8yrs	HK$1.22m	27.93% HK$ 50.8m
Ho Chung	CEO & Executive Director	12yrs	HK$1.22m	Veri yok
Yong Xing	Executive Director	3.3yrs	HK$300.00k	0.028% HK$ 51.7k
Jingming Wang	Non-Executive Director	10.6yrs	HK$100.00k	0.58% HK$ 1.1m
Xuejun Jiang	Independent Non-Executive Director	no data	HK$100.00k	Veri yok
Lianhai Huang	Non-Executive Director	no data	HK$100.00k	Veri yok
Yanhua Du	Independent Non-Executive Director	no data	HK$100.00k	Veri yok
Liangquan Lai	Independent Non-Executive Director	no data	HK$100.00k	Veri yok

9.3yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 673 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/28 20:52
Gün Sonu Hisse Fiyatı	2024/12/27 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

China Health Group Limited 0 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum

China Health Group Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Here's Why China Health Group Limited's (HKG:673) CEO Compensation Is The Least Of Shareholders' Concerns

Non-Executive Director recently bought HK$291k worth of stock

China Health Group Limited Announces Redesignation of Xing Yong from A Non- Executive Director to an Executive Director

China Health Group Limited, Annual General Meeting, Sep 12, 2024

Shareholders Will Probably Not Have Any Issues With China Health Group Limited's (HKG:673) CEO Compensation

China Health Group Limited, Annual General Meeting, Sep 18, 2023

Recent updates

First half 2025 earnings released: HK$0.035 loss per share (vs HK$0.032 loss in 1H 2024)

New major risk - Financial position

China Health Group Limited to Report First Half, 2025 Results on Nov 29, 2024

New minor risk - Share price stability

New minor risk - Share price stability

Here's Why China Health Group Limited's (HKG:673) CEO Compensation Is The Least Of Shareholders' Concerns

Non-Executive Director recently bought HK$291k worth of stock

China Health Group Limited Announces Redesignation of Xing Yong from A Non- Executive Director to an Executive Director

Full year 2024 earnings released: HK$0.085 loss per share (vs HK$0.099 loss in FY 2023)

China Health Group Limited, Annual General Meeting, Sep 12, 2024

New minor risk - Shareholder dilution

Full year 2024 earnings released: HK$0.084 loss per share (vs HK$0.099 loss in FY 2023)

China Health Group Limited to Report Fiscal Year 2024 Results on Jun 27, 2024

First half 2024 earnings released: HK$0.032 loss per share (vs HK$0.066 loss in 1H 2023)

New major risk - Revenue and earnings growth

China Health Group Limited to Report First Half, 2024 Results on Nov 30, 2023

Shareholders Will Probably Not Have Any Issues With China Health Group Limited's (HKG:673) CEO Compensation

New minor risk - Shareholder dilution

China Health Group Limited, Annual General Meeting, Sep 18, 2023

Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.03 loss in FY 2022)

New minor risk - Insider selling

Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.03 loss in FY 2022)

China Health Group Limited to Report Fiscal Year 2023 Results on Jun 30, 2023

Executive Chairman recently bought HK$932k worth of stock

First half 2023 earnings released: HK$0.066 loss per share (vs HK$0.013 loss in 1H 2022)

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

First half 2023 earnings released: HK$0.066 loss per share (vs HK$0.013 loss in 1H 2022)

China Health Group Limited Provides Earning Guidance for the Six Months Ended 30 September 2022

China Health Group Limited to Report First Half, 2023 Results on Nov 30, 2022

Less than half of directors are independent

We Discuss Why China Health Group Limited's (HKG:673) CEO May Deserve A Higher Pay Packet

China Health Group Limited, Annual General Meeting, Sep 30, 2022

Full year 2022 earnings released: HK$0.003 loss per share (vs HK$0.002 loss in FY 2021)

Full year 2022 earnings released

China Health Group Limited to Report Fiscal Year 2022 Results on Jun 30, 2022

China Health Group Limited announced that it expects to receive HKD 82 million in funding

Less than half of directors are independent

First half 2022 earnings: Revenues and EPS in line with analyst expectations

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Some Shareholders May Hesitate To Increase China Health Group Limited's (HKG:673) CEO Compensation

Full year 2021 earnings released: HK$0.002 loss per share (vs HK$0.009 loss in FY 2020)

No-Executive Director has left the company

China Health Group Limited Announces Board Changes

Did China Health Group Limited (HKG:673) Insiders Sell Shares?

First half 2021 earnings released: HK$0.001 loss per share

First half 2021 earnings released: HK$0.001 loss per share

China Health Group Limited to Report First Half, 2021 Results on Nov 30, 2020

Full year earnings released - HK$0.0089 loss per share

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları